A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL

Journal of Immunology

Volumn 163, Issue 1, 1999, Pages 184-193

  Matsui, So ^a   Ahlers, Jeffrey D ^a   Vortmeyer, Alex O ^a   Terabe, Masaki ^a   Tsukui, Taku ^a   Carbone, David P ^b   Liotta, Lance A ^a   Berzofsky, Jay A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GLYCOPROTEIN GP 160; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; EXPERIMENTAL MODEL; FEMALE; HELPER CELL; HISTOPATHOLOGY; IMMUNOSURVEILLANCE; LYMPHOCYTE DEPLETION; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REGULATORY MECHANISM; T LYMPHOCYTE ACTIVATION; TUMOR CELL DESTRUCTION; TUMOR ESCAPE; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR REGRESSION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CELL MOVEMENT; EPITOPES, T-LYMPHOCYTE; FEMALE; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; IMMUNITY, NATURAL; IMMUNOLOGIC SURVEILLANCE; INTERFERON TYPE II; LYMPHOCYTE DEPLETION; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MODELS, IMMUNOLOGICAL; NEOPLASM RECURRENCE, LOCAL; NEOPLASM TRANSPLANTATION; RNA, MESSENGER; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR ESCAPE; TUMOR VIRUS INFECTIONS;

EID: 0033168607     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Van der Bruggen, P., C. Traversari, P. Chomez, C. Lurquin, E. De Plaen, B. Van den Eynde, A. Knuth, and T. Boon. 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643.
2. Kawakami, Y., S. Eliyahu, C. H. Delgado, P. F. Robbins, K. Sakaguchi, E. Appella, J. R. Yannelli, G. J. Adema, T. Miki, and S. A. Rosenberg. 1994. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA 91:6458.
3. Coulie, P. G., V. Brichard, A. V. Pel, T. Wölfel, J. Schneider, C. Traversari, S. Mattei, E. De Plaen, C. Lurquin, J. -P. Szikora, J. -C. Renauld, and T. Boon. 1994. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180:35.
4. Cox, A. L., J. Skipper, Y. Chen, R. A. Henderson, T. L. Darrow, J. Shabanowitz, V. H. Engelhard, D. F. Hunt, and C. L. Slingluff, Jr. 1994. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716.
5. Herlyn, M., Z. Steplewski, D. Herlyn, and H. Koprowski. 1979. Colorectal carcinoma-spetific antigen: detection by means of monoclonal Abs. Proc. Natl. Acad. Sci. USA 76:1438.
6. Gendler, S., J. Taylor-Papadimitriou, T. Duhig, J. Rothbard, and J. Burchell. 1988. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J. Biol. Chem. 263: 12820.
7. Jerome, K. R., D. L. Barnd, K. M. Bendt, C. M. Boyer, J. Taylor-Papadimitriou, I. F. McKenzie, R. C. Bast, Jr., and O. J. Finn. 1991. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res. 51:2908.
8. + T lymphocytes, generated by mutant p21-ras (12VAL) peptide vaccination of a patient, recognize 12VAL-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. Int. J. Cancer 72:784.
9. Cheever, M. A., M. L. Disis, H. Bernhard, J. R. Gralow, S. L. Hand, E. S. Huseby, H. L. Qin, M. Takahashi, and W. Chen. 1995. Immunity to oncogenic proteins. Immunol. Rev. 145:33.
10. Henderson, R. A., and O. J. Finn. 1996. Human tumor antigens are ready to fly. Adv. Immunol. 62:217.
11. McCune, C. S., R. W. O'Donnell, D. M. Marquis, and D. M. Sahasrabudhe. 1990. Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells. Cancer Immunol. Immunother. 32:62.
12. Schlag, P., M. Manasterski, T. Gerneth, P. Hohenberger, M. Dueck, C. Herfarth, W. Liebrich, and V. Schirrmacher. 1992. Active specific immunotherapy with newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. Cancer Immunol. Immunother. 35:325.
13. Patel, B. T., M. B. Lutz, P. Schlag, and V. Schirrmacher. 1992. An analysis of autologous T-cell anti-tumor responses in colon-carcinoma patients following active specific immunization (ASI). Int. J. Cancer 51:878.
14. Morton, D. L., L. J. Foshag, D. S. Hoon, J. A. Nizze, E. Famatiga, L. A. Wanek, C. Chang, D. G. Davtyan, R. K. Gupla, R. Elashoff, and R. F. Irie. 1992. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann. Surg. 216:463.
15. Borysiewicz, L. K., A. Fiander, M. Nimako, S. Man, G. W. G. Wilkinson, D. Westmoreland, A. S. Evans, M. Adams, S. N. Staccy, M. E. G. Boursnell, et al. 1996. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347:1523.
16. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwartz, P. J. Spiess, et al. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:321.
17. Urban, J. L., R. C. Burton, J. M. Holland, M. L. Kripke, and H. Schreiber. 1982. Mechanisms of syngeneic tumor rejection. Susceptibility of host-selected progresser variants to various immunological effector cells. J. Exp. Med. 155:557.
18. + T-cell-dependent surveillance. Cancer Res. 50:3851.
19. Wojtowicz-Praga, S. 1997. Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J. Immunother. 20:165.
20. Uyttenhove, C., J. Maryanski, and T. Boon. 1983. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J. Exp. Med. 157:1040.
21. Momburg, F., A. Ziegler, J. Harpprecht, P. Moller, G. Moldenhauer, and G. J. Hammerling. 1989. Selective loss of HLA-A or HLA-B antigen expression in colon carcinoma. J. Immunol. 142:352.
22. 2-microglobulin mRNA in human colon carcinoma. J. Exp. Med. 169:309.
23. 2-microglobulin in HLA negative tumours. Scand. J. Immunol. 34:147.
24. Garrido, F., T. Cabrera, A. Concha, S. Glew, F. Ruiz-Cabello, and P. L. Stern. 1993. Natural history of HLA expression during tumour development. Immunol. Today 14:491.
25. Blanckaert, V. D., M. E. Schelling, C. A. Elstad, and G. G. Meadows. 1993. Differential growth factor production, secretion, and response by high and low metastatic variants of B16BL6 melanoma. Cancer Res. 53:4075.
26. Kim, J., R. L. Modlin, R. L. Moy, S. M. Dubinett, T. McHugh, and B. J. Nickoloff. 1995. IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. J. Immunol. 155:2240.
27. Maxwell, M., T. Galanopoulos, J. Neville-Golden, and H. N. Antoniades. 1992. Effect of the expression of transforming growth factor-Β2 in primary human glioblastomas on immunosuppression and loss of immune surveillance. J. Neurosurg. 76:799.
28. Arvind, P., E. D. Papavassiliou, G. J. Tsioulias, L. Qiao, C. I. Lovelace, B. Duceman, and B. Rigas. 1995. Prostaglandin E2 down-regulates the expression of HLA-DR antigen in human colon adenocarcinoma cell lines. Biochemistry 34:5604.
29. Browning, M. J., P. Krausa, A. Rowan, A. B. Hill, D. C. Bicknell, J. G. Bodmer, and W. F. Bodmer. 1993. Loss of human leukocyte antigen expression on colorectal tumor cell lines: implications for anti-tumor immunity and immunotherapy. J. Immunother. 14:163.
30. Hahne, M., D. Rimoldi, M. Schroter, P. Romero, M. Schreier, L. E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, J. Cerottini, and J. Tschopp. 1996. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 274:1363.
31. Saas, P., P. R. Walker, M. Hahne, A. L. Quiquerez, V. Schnuriger, G. Perrin, L. French, E. G. Van Meir, N. de Tribolet, J. Tschopp, and P. Y. Dietrich. 1997. Fas ligand expression by astrocytomas in vivo: maintaining immune privilege in the brain. J. Clin. Invest. 99:1173.
32. Strand, S., W. J. Hofmann, M. Muller, G. Otto, D. Strand, S. M. Mariani, W. Stremmel, P. H. Krammer, and P. R. Galle. 1996. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells-a mechanism of immune evasion? Nat. Med. 2:1361.
33. O'Connell, J., G. C. O'Sullivan, J. K. Collins, and F. Shanahan. 1996. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184:1075.
34. Kurokohchi, K., M. Carrington, D. L. Mann, T. B. Simonis, M. A. Alexander-Miller, S. M. Feinstone, T. Akatsuka, and J. A. Berzofsky. 1996. Expression of HLA class I molecules and the transporter associated with antigen preocessing (TAP) in hepatocellular carcinoma. Hepatology 23:1181.
35. Gabrilovich, D. I., S. Nadaf, J. Corak, J. A. Berzofsky, and D. P. Carbone. 1996. Dendritic cells in anti-tumor immune reponses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice are effective antigen carriers in the therapy of established tumors. Cell. Immunol. 170:111.
36. Gabrilovich, D. I., H. L. Chen, K. R. Girgis, H. T. Cunningham, G. M. Meny, S. Nadaf, D. Kavanaugh, and D. P. Carbone. 1996. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. [Published erratum appears in 1996 Nat. Med. 2:1267] Nat. Med. 2:1096.
37. Oyama, T., S. Ran, T. Ishida, S. Nadaf, L. Kerr, D. P. Carbone, and D. I. Gabrilovich. 1998. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-κB activation in hemopoietic progenitor cells. J. Immunol. 160:1224.
38. Takahashi, H., J. Cohen, A. Hosmalin, K. B. Cease, R. Houghten, J. Cornette, C. DeLisi, B. Moss, R. N. Germain, and J. A. Berzofsky. 1988. An immuno-dominant epitope of the HIV gp160 envelope glycoprotein recognized by class I MHC molecule-restricted murine cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA 85:3105.
39. Takahashi, H., S. Merli, S. D. Putney, R. Houghten, B. Moss, R. N. Germain, and J. A. Berzofsky. 1989. A single amino acid interchange yields reciprocal CTL specificities for HIV gp160. Science 246:118.
40. Takahashi, H., R. Houghten, S. D. Putney, D. H. Margulies, B. Moss, R. N. Germain, and J. A. Berzofsky. 1989. Structural requirements for class-1 MHC molecule-mediated antigen presentation and cytotoxic T-cell recognition of an immunodominant determinant of the HIV envelope protein. J. Exp. Med. 170:2023.
41. Shirai, M., C. D. Pendleton, and J. A. Berzofsky. 1992. Broad recognition of cytotoxic T-cell epitopes from the HIV-1 envelope protein with multiple class I histocompatibility molecules. J. Immunol. 148:1657.
42. Shirai, M., M. S. Vacchio, R. J. Hodes, and J. A. Berzofsky. 1993. Preferential VΒ usage by cytotoxic T cells crossreactive between two epitopes of HIV-1 gp160 and degenerate in class I MHC restriction. J. Immunol. 151:2283.
43. Ahlers, J. D., C. D. Pendleton, N. Dunlop, A. Minassian, P. L. Nara, and J. A. Berzofsky. 1993. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing Ab responses in mice of multiple MHC haplotypes after two immunizations. J. Immunol. 150:5647.
44. + CTL in vivo with peptide vaccine constructs. J. Immunol. 152:549.
45. Takeshita, T., H. Takahashi, S. Kozlowski, J. D. Ahlers, C. D. Pendleton, R. L. Moore, Y. Nakagawa, K. Yokomuro, B. S. Fox, D. H. Margulies, and J. A. Berzofsky. 1995. Molecular analysis of the same HIV peptide functionally binding to both a class I and a class II MHC molecule. J. Immunol. 154:1973.
46. Berzofsky, J. A., and I. J. Berkower. 1995. Novel approaches to peptide and engineered protein vaccines for HIV using defined epitopes: advances in 1994-95. AIDS 9(Suppl. A):S143.
47. Ahlers, J. D., N. Dunlop, C. D. Pendleton, M. Newman, P. L. Nara, and J. A. Berzofsky. 1996. Candidate HIV type 1 multideterminant cluster peptide-P18 MN vaccine constructs elicit type1 helper T cells, cytotoxic T cells, and neutralizing Ab, all using the same adjuvant immunization. AIDS Res. Hum. Retroviruses 12:259.
48. Alexander-Miller, M. A., G. R. Leggatt, and J. A. Berzofsky. 1996. Selective expansion of high or low avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. USA 93:4102.
49. Kobayashi, M., H. Kobayashi, R. B. Pollard, and F. Suzuki. 1998. A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 melanoma. J. Immunol 160:5869.
50. Bloom, B. R., P. Salgame, and B. Diamond. 1992. Revisiting and revising suppressor T cells. Immunol. Today 13:131.
51. Zitvogel, L., J. I. Mayordomo, T. Tjandrawan, A. B. DeLeo, M. R. Clarke, M. T. Lotze, and W. J. Storkus. 1996. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 183:87.
52. Tsung, K., J. B. Meko, G. R. Peplinski, Y. L. Tsung, and J. A. Norton. 1997. 1L-12 induces T helper 1-directed antiutmor response. J. Immunol. 158:3359.
53. Weiner, G. J., H. -M. Liu, J. E. Wooldridge, C. E. Dahle, and A. M. Krieg. 1997. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl. Acad. Sci. USA 94:10833.
54. Hu, H. -M., W. J. Urba, and B. A. Fox. 1998. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile. J. Immunol. 161:3033.
55. Tsukui, T., A. Hildesheim, M. H. Schiffman, J. Lucci III, D. Contois, P. Lawler, B. B. Rush, A. T. Lorincz, A. Corrigan, R. D. Burk, et al. 1996. IL-2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology. Cancer Res. 56:3967.
56. Earl, P. L., A. W. Hugin, and B. Moss. 1990. Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus. J. Virol. 64:2448.
57. Chakrabarti, S., K. Brechung, and B. Moss. 1985. Vaccinia virus expression vector: coexpression of Β-galactosidase provides visual screening of recombinant virus plaques. Mol. Cell. Biol. 5:3403.
58. + CTL by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells. Int. Immunol. 5:849.
59. Abbas, A. K., K. M. Murphy, and A. Sher. 1996. Functional diversity of helper T lymphocytes. Nature 383:787.
60. McAdam, A. J., B. A. Pulaski, S. S. Harkins, E. K. Hutter, E. M. Lord, and J. G. Frelinger. 1995. Synergistic effects of co-expressin of the TH1 cytokines 1L-2 and IFN-γ on generation of murine tumor-reative cytotoxic cells. Int. J. Cancer 61:628.
61. Yamamura, M., R. L. Modlin, J. D. Ohmen, and R. L. Moy. 1993. Local expression of antiinflammatory cytokines in cancer. J. Clin. Invest. 91:1005.
62. + T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol. Immunother. 42:1.
63. Maeda, H., and A. Shiraishi. 1996. TGF-Β contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. J. Immunol. 156:73.
64. Kono, D. H., D. Balomenos, D. L. Pearson, M. S. Park, B. Hildebrandt, P. Hultman, and K. M. Pollard. 1998. The prototypic Th2 autoimmunity induced by mercury is dependent on IFN-γ and not Th1/Th2 imbalance. J. Immunol. 161:234.
65. Kühn, R., K. Rajewsky, and W. Müller. 1991. Generation and analysis of interleukin-4 deficient mice. Science 254:707.
66. Swain, S. L., A. D. Weinberg, M. English, and G. Huston. 1990. IL-4 directs the development of Th2-like helper effectors. J. Immunol. 145:3796.
67. Kopf, M., G. Le Gros, M. Bachmann, M. C. Lamers, H. Bluethmann, and G. Köhler. 1993. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 362:245.
68. Kopf, M., F. Brombacher, G. Köhler, G. Kienzle, K-H. Widmann, K. Lefrang, C. Humborg, B. Ledermann, and W. Solbach. 1996. IL-4-deficient Balb/c mice resist infection with Leishmania major. J. Exp. Med. 184:1127.
69. Pearce, E. J., A. Cheever, S. Leonard, M. Covalesky, R. Fernandez-Botran, G. Kohler, and M. Kopf. 1995. Shistosoma mansoni in IL-4-deficient mice. Int. Immunol. 8:435.
70. Koeppen, H. K. W., S. Singh, H. J. Stauss, B. H. Park, D. A. Rowley, and H. Schreiber. 1993. CD4-positive and B lymphocytes in transplantation immunity I. Promotion of tumor allograft rejection through elimination of CD4-positive lymphocytes. Transplantation 55:1349.
71. + T cells in mice bearing an advanced sarcoma augments the antitumor action of interleukin-2. Cancer Immunol. Immunother. 38:107.
72. Martinotti, A., A. Stoppacciaro, M. Vagliani, C. Melani, F. Spreafico, M. Wysocka, G. Parmiani, G. Trinchieri, and M. P. Colombo. 1995. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Eur. J. Immunol. 25:137.
73. Bronte, V., K. Tsung, J. B. Rao, P. W. Chen, M. Wang, S. A. Rosenberg, and N. P. Restifo. 1995. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J. Immunol. 154:5282.